Clinical Reviews in Allergy & Immunology

, Volume 32, Issue 2, pp 178–183 | Cite as

The Heart and APS



The heart is a target organ in antiphospholipid syndrome (APS). Endocardial disease, intracardiac thrombosis, myocardial involvement including coronary heart disease and microvascular thrombosis, as well as pulmonary hypertension have all been described in APS patients. Valvular involvement is the most common manifestation with a prevalence of 82% detected by transesophageal echocardiography. Symmetrical, nodular thickening of the mitral and/or aortic valves is characteristic. Anticoagulant/antiplatelet treatment is ineffective in terms of valvular lesion regression. Some patients require cardiac valve replacement. However, patients with APS have shown an increased perioperative morbidity and mortality. Intracardiac thrombosis, although a rare complication, can cause pulmonary and systemic emboli. Differential diagnosis with myxoma may be very difficult.


Valve disease Antiphospholipid syndrome Intracardiac thrombosis 


  1. 1.
    Hughes GRV, Harris EN, Gharavi AE (1986) The anticardiolipin syndrome. J Rheumatol 13:486–489PubMedGoogle Scholar
  2. 2.
    Cervera R, Khamashta M, Font J et al (1991) High prevalence of significant heart valve lesions in patients with the “primary” antiphospholipid syndrome. Lupus 1:43–47PubMedGoogle Scholar
  3. 3.
    Galve E, Ordi J, Barquinero J et al (1992) Valvular heart disease in the primary antiphospholipid syndrome. Ann Intern Med 116:293–298PubMedGoogle Scholar
  4. 4.
    Badui E, Solorio S, Martínez E et al (1995) The heart in the primary antiphospholipid syndrome. Arch Med Res 26:115–120PubMedGoogle Scholar
  5. 5.
    Vianna JL, Khamashta MA, Ordi-Ros J et al (1994) Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med 96:3–9PubMedCrossRefGoogle Scholar
  6. 6.
    Nesher G, Ilany J, Rosenmann D et al (1997) Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum 27:27–35PubMedCrossRefGoogle Scholar
  7. 7.
    Espínola-Zavaleta N, Vargas-Barrón J, Colmenares T et al (1999) Echocardiographic evaluation of patients with primary antiphospholipid syndrome. Am Heart J 137:974–979Google Scholar
  8. 8.
    Turiel M, Muzzupappa S, Gottardi B, Crema C, Sarzi-Puttini P, Rossi E (2000) Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography. Lupus 9:406–412PubMedCrossRefGoogle Scholar
  9. 9.
    Qaddoura F, Connolly H, Grogan M, Orszulak TA, Schaff HV, Chandrasekaran K, Click RL (2005) Valve morphology in antiphospholipid antibody syndrome: echocardiographic features. Echocardiography 22:255–259PubMedCrossRefGoogle Scholar
  10. 10.
    Espínola-Zavaleta N, Amigo MC, Vargas-Barrón et al (2001) Two- and three-dimensional echocardiography in primary antiphospholipid syndrome: misdiagnosis as rheumatic valve disease. Lupus 10:511–513PubMedCrossRefGoogle Scholar
  11. 11.
    Turiel M, Sarzi-Puttini P, Peretti R et al (2005) Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am J Cardiol 96:574–579PubMedCrossRefGoogle Scholar
  12. 12.
    García-Torres R, Amigo MC, de la Rosa A et al (1996) Valvular heart disease in primary antiphospholipid syndrome (PAPS): clinical and morphological findings. Lupus 5:56–61PubMedGoogle Scholar
  13. 13.
    Ziporen L, Goldberg I, Arad MY et al (1996) Libman–Sacks endocarditis in the antiphospholipid syndrome; immunopathologic findings in deformed heart valves. Lupus 5:196–205PubMedGoogle Scholar
  14. 14.
    Afek A, Shoenfeld Y, Manor R et al (1999) Increased endothelial cell expression of α3β1 integrin in cardiac valvulopathy in the primary (Hughes) and secondary antiphospholipid syndrome. Lupus 8:502–507PubMedCrossRefGoogle Scholar
  15. 15.
    Espínola-Zavaleta N, Montes RM, Soto ME, Avila Vanzzini A, Amigo MC (2004) Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic followup study. J Rheumatol 31:2402–2407Google Scholar
  16. 16.
    Petri M (2004) Classification criteria for antiphospholipid syndrome: the case for cardiac valvular disease. J Rheumatol 31:2329–2330PubMedGoogle Scholar
  17. 17.
    Agirbasli MA, Hansen DE, Byrd BF (1997) Resolution of vegetations with anticoagulation after myocardial infarction in primary antiphospholipid syndrome. J Am Soc Echocardiogr 10:877–880PubMedCrossRefGoogle Scholar
  18. 18.
    Nesher G, Ilany J, Rosenmann D, Abraham AS (1997) Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum 27:27–35PubMedCrossRefGoogle Scholar
  19. 19.
    Hojnik M, George J, Ziporen L, Shoenfeld Y (1996) Heart valve involvement (Libman–Sacks endocarditis) in the antiphospholipid syndrome. Circulation 93:1579–1587PubMedGoogle Scholar
  20. 20.
    Lockshin M, Tenedios F, Petri M, Mc Carty G, Forastiero R, Krilis S et al (2003) Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus 12:518–523PubMedCrossRefGoogle Scholar
  21. 21.
    Tenedios F, Erkan D, Lockshin MD (2005) Cardiac involvement in the antiphospholipid syndrome. Lupus 14:691–696PubMedCrossRefGoogle Scholar
  22. 22.
    Erkan D, Yazici Y, Sobel R, Lockshin MD (2000) Primary antiphospholipid syndrome: functional outcome after 10 years. J Rheumatol 27:2817–2821PubMedGoogle Scholar
  23. 23.
    Yoshida M, Sasako Y, Kobayashi J et al (2000) Mitral valve plasty in systemic lupus erythematosus in the setting of antiphospholipid syndrome. Jpn J Thorac Cardiovasc Surg 48:391–393PubMedGoogle Scholar
  24. 24.
    Myerowitz PD, Michaelis LL, McIntosh CL (1974) Mitral valve replacement for mitral regurgitation due to Libman–Sacks endocarditis. J Thorac Cardiovasc Surg 67:869–874PubMedGoogle Scholar
  25. 25.
    Dajee H, Hurley EJ, Szarnicki RJ (1983) Cardiac valve replacement in systemic lupus erythematosus. J Thorac Cardiovasc Surg 85:718–726PubMedGoogle Scholar
  26. 26.
    Hakim JP, Mehta A, Jain AC, Murray GF (2001) Mitral valve replacement and repair. Report of 5 patients with systemic lupus erythematosus. Texas Heart Inst J 28:47–52Google Scholar
  27. 27.
    Vaughton KC, Walker DR, Sturridge MF (1979) Mitral valve replacement for mitral stenosis caused by Libman–Sacks endocarditis. Br Heart J 41:730–733PubMedCrossRefGoogle Scholar
  28. 28.
    Ciocca RG, Choi J, Graham AM (1995) Antiphospholipid antibodies lead to increase risk in cardiovascular surgery. Am J Surg 170:198–200PubMedCrossRefGoogle Scholar
  29. 29.
    Berkun Y, Elami A, Meir K, Mevorach D, Naparstek Y (2004) Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. J Thorac Cardiovasc Surg 127:414–420PubMedCrossRefGoogle Scholar
  30. 30.
    Massoudy P, Cetin SM, Thiemann M et al (2005) Antiphospholipid syndrome in cardiac surgery—an underestimated coagulation disorder? Eur J Cardio-thorac Surg 28:133–137CrossRefGoogle Scholar
  31. 31.
    Dornan RIP (2004) Acute postoperative biventricular failure associated with antiphospholipid antibody syndrome. Br J Anaesth 92:748–754PubMedCrossRefGoogle Scholar
  32. 32.
    Erkan D, Leibowitz E, Berman J, Lockshin MD (2002) Perioperative management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations. J Rheumatol 29:843–849PubMedGoogle Scholar
  33. 33.
    Sheikh F, Lechowics A, Setkur R, Rauch A, Dunn H (1997) Recognition and management of patients with antiphospholipid antibody syndrome undergoing cardiac surgery. J Cardiothorac Vasc Anesth 11:764–766PubMedCrossRefGoogle Scholar
  34. 34.
    Hogan WJ, Mc Bane RD, Santrach PJ et al (2000) Antiphospholipid syndrome and perioperative hemostatic management of cardiac valvular surgery. Mayo Clin Proc 75:971–976PubMedCrossRefGoogle Scholar
  35. 35.
    Ducart AR, Collard EL, Osselaer JC et al (1997) Management of anticoagulation during cardiopulmonary bypass in a patient with a circulating lupus anticoagulant. J Cardiothoracic Vasc Anesth 11:878–879CrossRefGoogle Scholar
  36. 36.
    East CJ, Clements F, Mathew J, Slaughter TF (2000) Antiphospholipid syndrome and cardiac surgery: management of anticoagulation in two patients. Anesth Analg 90:1098–1101PubMedCrossRefGoogle Scholar
  37. 37.
    Asherson RA, Gibson DG, Evans DW, Baguley E, Hughes GR (1988) Diagnostic and therapeutic problems in two patients with antiphospholipid antibodies, heart valve lesions, and transient ischemic attacks. Ann Rheum Dis 47:947–953PubMedCrossRefGoogle Scholar
  38. 38.
    Font J, Cervera R (2000) Cardiac manifestations in the antiphospholipid syndrome. In: Khamashta MA (ed) Hughes Syndrome. The antiphospholipid syndrome. London, Springer-Verlag, pp 32–42Google Scholar
  39. 39.
    Pope JM, Canny CL, Bell DA (1991) Cerebral ischemic events associated with endocarditis, retinal vascular disease, and lupus anticoagulant. Am J Med 90:299–309PubMedGoogle Scholar
  40. 40.
    Barbut D, Borer JS, Gharavi A et al (1992) Prevalence of anticardiolipin antibody in isolated mitral or aortic regurgitation, or both, and possible relation to cerebral ischemic events. Am J Cardiol 70:901–905PubMedCrossRefGoogle Scholar
  41. 41.
    Pamuk ON, Cakir N, Soy M, Aktoz M, Celik Y, Akdemir O (2003) Mitral valve vegetation and cerebral emboli in a primary antiphospholipid syndrome patient who had hepatitis C virus infection: report of a case and review of the literature. Clin Rheumatol 22:136–139PubMedCrossRefGoogle Scholar
  42. 42.
    Erdogan D, Goren T, Diz-Kucukkaya R, Inanc M (2005) Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome. A transesophageal echocardiographic study. Stroke 36:592–596PubMedCrossRefGoogle Scholar
  43. 43.
    Krause I, Lev S, Fraser A et al (2005) Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis 64:1490–1493PubMedCrossRefGoogle Scholar
  44. 44.
    Leventhal LJ, Borofsky MA, Bergey PD, Schumacher HR Jr (1989) Antiphospholipid antibody syndrome with right atrial thrombosis mimicking an atrial myxoma. Am J Med 87:111–113PubMedCrossRefGoogle Scholar
  45. 45.
    Brancaccio G, Di Gioia C, Prifti E, Dámati G, Michielon G, Miraldi F (2002) Antiphospholipid antibodies and intracardiac thrombosis. A case report. J Cardiovasc Surg (Torino) 43:479–482Google Scholar
  46. 46.
    Granel B, Garcia E, Serratrice J et al (1999) Asymptomatic intracardiac thrombi and primary antiphospholipid syndrome. Cardiology 92:65–67PubMedCrossRefGoogle Scholar
  47. 47.
    Denie C, Lefebvre C, Dion R, Coche E (1994) Thrombus of the right atrium simulating myxoma in primary antiphospholipid syndrome. Rev Med Intern 15:409–411CrossRefGoogle Scholar
  48. 48.
    Gertner E, Leatherman JW (1992) Intracardiac mural thrombus mimicking atrial myxoma in the antiphospholipid syndrome. J Rheumatol 19:1293–1298PubMedGoogle Scholar
  49. 49.
    Esteban E, Blanes A, Moreno MT, Cánovas SJ, Montero JA, Sotillo JF (2002) Mixoma auricular derecho en paciente con anticuerpos antifosfolipídicos positivos. Rev Esp Cardiol 55:999–1002PubMedGoogle Scholar
  50. 50.
    Erkan D, Erel H, Yazici Y, Prince MR (2002) The role of cardiac magnetic resonance imaging in antiphospholipid syndrome. J Rheumatol 29:2658–2659PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  1. 1.Instituto Nacional de Cardiología Ignacio ChávezUniversidad Nacional Autónoma de MéxicoMexico CityMexico
  2. 2.ABC Medical CenterMexico CityMexico

Personalised recommendations